CohBar (CWBR) 10-Q 15 May 15 2015 Q1 Quarterly report Financial data

Document_And_Entity_Informatio

Document And Entity Information	3 Months Ended
	Mar. 31, 2015	11-May-15
Document Information [Line Items]
Document Type	10-Q
Amendment Flag	FALSE
Document Period End Date	31-Mar-15
Document Fiscal Year Focus	2015
Document Fiscal Period Focus	Q1
Entity Registrant Name	CohBar, Inc.
Entity Central Index Key	1522602
Current Fiscal Year End Date	-19
Entity Filer Category	Smaller Reporting Company
Trading Symbol	COB.U
Entity Common Stock, Shares Outstanding		32,320,891

Condensed_Balance_Sheets

Condensed Balance Sheets (USD $)	Mar. 31, 2015	Dec. 31, 2014
Current assets:
Cash and cash equivalents	$9,952,751	$1,194,492
Restricted cash	0	4,055
Marketable securities	3,247,509	0
Prepaid expenses and other current assets	83,029	19,517
Total current assets	13,283,289	1,218,064
Property and equipment, net	16,359	4,631
Deferred offering costs	0	749,386
Other assets	16,308	1,100
Total assets	13,315,956	1,973,181
Current liabilities:
Accounts payable	164,484	290,073
Accrued liabilities	208,281	305,401
Accrued payroll and other compensation	75,154	103,294
Total current liabilities	447,919	698,768
Note payable, net of debt discount of $402 and $451 as of March 31, 2015 and December 31, 2014, respectively	204,858	204,809
Total liabilities	652,777	903,577
Commitments and contingencies
Stockholders’equity
Common stock, $0.001 par value, Authorized-75,000,000 shares; Issued and outstanding 32,320,891 shares as of March 31, 2015 and 12,915,343 as of December 31, 2014	32,321	12,915
Additional paid-in capital	17,868,450	5,507,616
Accumulated deficit	-5,237,592	-4,456,327
Total stockholders’ equity	12,663,179	1,069,604
Total liabilities and stockholders’ equity	13,315,956	1,973,181
Series A Preferred Stock [Member]
Stockholders’equity
Preferred Stock	0	0
Convertible Preferred Stock Series B [Member]
Stockholders’equity
Preferred Stock	$0	$5,400

Condensed_Balance_Sheets_Paren

Condensed Balance Sheets (Parenthetical) (USD $)	Mar. 31, 2015	Dec. 31, 2014
Debt Instrument, Unamortized Discount	$402	$451
Preferred Stock, Par or Stated Value Per Share	$0.00	$0.00
Preferred Stock, Shares Authorized	5,000,000	5,000,000
Common Stock, Par or Stated Value Per Share	$0.00	$0.00
Common Stock, Shares Authorized	75,000,000	75,000,000
Common Stock, Shares, Issued	32,320,891	12,915,343
Common Stock, Shares, Outstanding	32,320,891	12,915,343
Series A Preferred Stock [Member]
Preferred Stock, Shares Issued	0	0
Preferred Stock, Shares Outstanding	0	0
Convertible Preferred Stock Series B [Member]
Preferred Stock, Shares Issued	0	5,400,000
Preferred Stock, Shares Outstanding	0	5,400,000

Condensed_Statements_of_Operat

Condensed Statements of Operations (USD $)	3 Months Ended
	Mar. 31, 2015	Mar. 31, 2014
Revenues	$0	$0
Operating expenses:
Research and development	262,760	111,708
General and administrative	516,986	140,913
Total operating expenses	779,746	252,621
Operating loss	-779,746	-252,621
Other income (expense):
Interest income	1,177	31
Interest expense	-1,756	-1,740
Other expense	-891	0
Amortization of debt discount	-49	-80
Total other income (expense)	-1,519	-1,789
Net loss	($781,265)	($254,410)
Basic and diluted net loss per share	($0.03)	($0.02)
Weighted average common shares outstanding - basic and diluted	31,198,876	12,915,343

Condensed_Statements_of_Cash_F

Condensed Statements of Cash Flows (USD $)	3 Months Ended
	Mar. 31, 2015	Mar. 31, 2014
Cash flows from operating activities:
Net loss	($781,265)	($254,410)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	550	624
Stock-based compensation	145,514	362
Amortization of debt discount	49	80
Changes in operating assets and liabilities:
Restricted cash	4,055	30,844
Prepaid expenses and other current assets	-63,512	-2,783
Accounts payable	-125,589	41,206
Accrued liabilities	-97,120	9,813
Accrued payroll and other compensation	-28,140	1,079
Net cash used in operating activities	-945,458	-173,185
Cash flows from investing activities:
Purchases of property and equipment	-12,278	0
Payment for security deposit	-15,207	0
Investments in marketable securities	-3,247,509	0
Net cash used in investing activities	-3,274,994	0
Cash flows from financing activities:
Deferred offering costs	-30,321	-14,982
Proceeds from convertible notes	0	210,000
Debt issuance costs	0	-24,471
Proceeds from initial public offering	10,253,484	0
Proceeds from exercise of stock options	55,548	0
Proceeds from conversion of private placement Puts	2,700,000	0
Net cash provided by financing activities	12,978,711	170,547
Net increase (decrease) in cash	8,758,259	-2,638
Cash at beginning of period	1,194,492	145,170
Cash at end of period	9,952,751	142,532
Non-cash investing and financing activities:
Warrants issued in connection with bridge loans	0	137
Reclassification of deferred offering costs to equity	779,707	0
Conversion of Series B Preferred Stock to Common Stock	$5,400,000	$0

Business_Organization

Business Organization	3 Months Ended
	Mar. 31, 2015
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]	Note 1 - Business Organization
	CohBar, Inc. (“CohBar” or the “Company”) is a leader in the research and development of mitochondria-based therapeutics (MBTs), an emerging class of drugs for the treatment of diseases associated with aging. MBTs originate from the discovery by the Company’s founders of a novel group of peptides within the genome of mitochondria, the powerhouses of the cell. The Company’s ongoing development of these mitochondrial-derived peptides (MDPs) into MBTs offers the potential to address a broad range of diseases such as type 2 diabetes, cancer, atherosclerosis and neurodegenerative disorders.
	The Company’s primary activities since inception have been the development and implementation of its business plans, negotiating inbound intellectual property licenses and other agreements, raising capital and conducting research on its MDPs. To date, the Company has not generated any revenues from operations and does not expect to generate any revenues in the near future.
	The unaudited interim condensed financial statements of the Company have been prepared in accordance with United States generally accepted accounting principles (“GAAP”) for interim financial information and the rules and regulations of the Securities and Exchange Commission (“SEC”). They do not include all information and footnotes required by GAAP for complete financial statements. Except as disclosed herein, there have been no material changes in the information disclosed in the notes to the financial statements for the year ended December 31, 2014, included in the Company’s Annual Report on Form 10-K, filed with the SEC (the “2014 Form 10-K”). The interim unaudited condensed financial statements should be read in conjunction with those audited financial statements included in the 2014 Form 10-K. In the opinion of management, all adjustments considered necessary for fair presentation, consisting solely of normal recurring adjustments, have been made. Operating results for the three month period ended March 31, 2015 are not necessarily indicative of the results that may be expected for the year ending December 31, 2015, or any other period.

Managements_Liquidity_Plans

Management's Liquidity Plans	3 Months Ended
	Mar. 31, 2015
Management's Liquidity Plans [Abstract]
Management's Liquidity Plans [Text Block]	Note 2 - Management’s Liquidity Plans
	As of March 31, 2015, the Company had working capital and stockholders’ equity of $12,835,370 and $12,663,179, respectively. During the three months ended March 31, 2015, the Company incurred a net loss of $781,265. The Company has not generated any revenues, has incurred net losses since inception and does not expect to generate revenues in the near term.
	In January 2015, the Company completed its Initial Public Offering (”IPO”) on the TSX Venture Exchange. The Company sold 11,250,000 units at a price of $1.00 per unit, providing gross proceeds of $11,250,000. Concurrently with the IPO, the Company completed a previously-subscribed private placement of an additional 2,700,000 units for gross proceeds of $2,700,000, resulting in total gross proceeds of $13,950,000.
	With the cash on hand as of March 31, 2015 the Company believes that it has sufficient cash to meet its working capital needs and operating expenses into the early part of 2017. However, if unanticipated difficulties arise the Company may be required to raise additional capital to support its operations or curtail its research and development activities until such time as additional capital becomes available. There is no assurance that additional financing will be available when needed or that management will be able to obtain such financing on terms acceptable to the Company and that the Company will become profitable and generate positive operating cash flow in the future.

Summary_of_Significant_Account

Summary of Significant Accounting Policies	3 Months Ended
	Mar. 31, 2015
Accounting Policies [Abstract]
Significant Accounting Policies [Text Block]	Note 3 - Summary of Significant Accounting Policies
	Basis of Presentation
	All amounts are presented in U.S. Dollars.
	Use of Estimates
	The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent liabilities at dates of the financial statements and the reported amounts of revenue and expenses during the periods. Actual results could differ from these estimates. The Company’s significant estimates and assumptions include the fair value of the Company’s stock, stock-based compensation, debt discount and the valuation allowance relating to the Company’s deferred tax assets.
	Concentrations of Credit Risk
	The Company maintains deposits in a financial institution which is insured by the Federal Deposit Insurance Corporation (“FDIC”). At various times, the Company has deposits in this financial institution in excess of the amount insured by the FDIC.
	Marketable Securities
	Marketable securities, which consists of U.S Treasury Bills and Certificates of Deposit, are classified as held-to-maturity. Held-to-maturity securities represent those securities that the Company has both a positive intent and ability to hold the security until maturity. The Company determines the appropriate balance sheet classification of its investments at the time of purchase and evaluates the classification at each balance sheet date.
	The Company had $3,247,509 and $0 of held-to-maturity securities at March 31, 2015 and December 31, 2014, respectively.
	Deferred Offering Costs
	The Company classifies amounts related to the IPO not closed as of the balance sheet date as Deferred Offering Costs. During the three months ended March 31, 2015, the Company reclassified Deferred Offering Costs in the amount of $749,386 to Additional Paid-in-Capital as an offset to its IPO.
	During the three months ended March 31, 2015, the Company incurred $30,321 of additional offering related costs. These costs were recorded as a reduction in Additional Paid-in-Capital in the accompanying condensed balance sheets.
	Fair Value of Financial Instruments
	The Company measures the fair value of financial assets and liabilities based on the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. The Company utilizes three levels of inputs that may be used to measure fair value:
	Level 1 - quoted prices in active markets for identical assets or liabilities
	Level 2 - quoted prices for similar assets and liabilities in active markets or inputs that are observable
	Level 3 - inputs that are unobservable (for example, cash flow modeling inputs based on assumptions)
	The carrying amounts of cash, marketable securities, accounts payable, accrued liabilities and debt approximate fair value due to the short-term nature of these instruments.
	Common Stock Purchase Warrants
	The Company classifies as equity any contracts that (i) require physical settlement or net-share settlement or (ii) provides the Company with a choice of net-cash settlement or settlement in its own shares (physical settlement or net-share settlement) providing that such contracts are indexed to the Company's own stock. The Company classifies as assets or liabilities any contracts that (i) require net-cash settlement (including a requirement to net cash settle the contract if an event occurs and if that event is outside the Company’s control), or (ii) gives the counterparty a choice of net-cash settlement or settlement in shares (physical settlement or net-share settlement). The Company assesses classification of its common stock purchase warrants and other free standing derivatives at each reporting date to determine whether a change in classification between assets and liabilities is required.  The Company’s free standing derivatives consist of warrants to purchase common stock that were issued in connection with its notes payable, warrants to purchase common stock that were issued in connection with the Company’s IPO and concurrent private placement and compensation options issued to the agent’s in the IPO exercisable for shares of common stock and common stock purchase warrants. The Company evaluated these warrants to assess their proper classification using the applicable criteria enumerated under U.S. GAAP and determined that the common stock purchase warrants meet the criteria for equity classification in the condensed balance sheet as of March 31, 2015 and December 31, 2014.
	Share-Based Payment
	The Company accounts for share-based payments using the fair value method. For employees and directors, the fair value of the award is measured, as discussed below, on the grant date. For non-employees, fair value is generally valued based on the fair value of the services provided or the fair value of the equity instruments on the measurement date, whichever is more readily determinable and re-measured on each financial reporting dates until the service is complete. The Company has granted stock options at exercise prices no less than the fair market value as determined by the board of directors, with input from management.
	The weighted-average fair value of options and warrants has been estimated on the date of grant using the Black-Scholes pricing model. The fair value of each instrument is estimated on the date of grant utilizing certain assumptions for a risk free interest rate, volatility and expected remaining lives of the awards. Since the Company has a limited history of being publicly traded, the fair value of stock-based payment awards issued before the Company’s IPO  was estimated using a volatility derived from an index of comparable entities. Stock-based awards that were issued during the three months ended March 31, 2015, after the Company’s IPO,  were estimated using the volatility derived from the Company’s common stock, which was not materially different than using an index of Comparable entities. The assumptions used in calculating the fair value of share-based payment awards represent management’s best estimates, but these estimates involve inherent uncertainties and the application of management judgment. As a result, if factors change and the Company uses different assumptions, the Company’s stock-based compensation expense could be materially different in the future. In addition, the Company is required to estimate the expected forfeiture rate and only recognize expense for those shares expected to vest. In estimating the Company’s forfeiture rate, the Company analyzed its historical forfeiture rate, the remaining lives of unvested options, and the number of vested options as a percentage of total options outstanding. If the Company’s actual forfeiture rate is materially different from its estimate, or if the Company reevaluates the forfeiture rate in the future, the stock-based compensation expense could be significantly different from what the Company has recorded in the current period.
	The weighted-average Black-Scholes assumptions are as follows:
		For The Three Months Ended March 31,
		2015			2014
	Expected life		2 years			1 year
	Risk free interest rate		0.65	%		0.13	%
	Expected volatility		80	%		132	%
	Expected dividend yield		0	%		0	%
	As of March 31, 2015, total unrecognized stock option compensation expense is $838,163, which will be recognized as those options vest over a period of approximately four years. The amount of future stock option compensation expense could be affected by any future option grants or by any option holders leaving the Company before their grants are fully vested.
	Net Loss Per Share of Common Stock
	Basic net loss per share is computed by dividing net loss attributable to common stockholders by the weighted average number of common shares outstanding during the period.  Diluted net earnings per share reflects the potential dilution that could occur if securities or other instruments to issue common stock were exercised or converted into common stock.  Potentially dilutive securities are excluded from the computation of diluted net loss per share as their inclusion would be anti-dilutive and consist of the following:
			March 31,			March 31,
			2015			2014
	Warrants			7,936,391			36,542
	Options			3,340,959			163,971
	Convertible notes			-			210,000
	Totals			11,277,350			410,513
	Recent Accounting Pronouncements
	Recent accounting standards that have been issued or proposed by the FASB or other standards-setting bodies that do not require adoption until a future a date are not expected to have a material impact on the Company’s financial statements upon adoption.

Accrued_Expenses

Accrued Expenses	3 Months Ended
	Mar. 31, 2015
Payables and Accruals [Abstract]
Accounts Payable and Accrued Liabilities Disclosure [Text Block]	Note 4 – Accrued Expenses
	Accrued expenses consist of:
		As of		As of
		March 31, 2015		December 31, 2014
	Lab services	$	36,579	$	64,768
	Professional fees		107,143		173,829
	Consultant fees		52,000		52,000
	Interest		12,559		10,804
	Expense reimbursement		-		4,000
	Total accrued expenses	$	208,281	$	305,401

Commitments_and_Contingencies

Commitments and Contingencies	3 Months Ended
	Mar. 31, 2015
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies Disclosure [Text Block]	Note 5 - Commitments and Contingencies
	Litigations, Claims and Assessments
	The Company may be involved in legal proceedings, claims and assessments arising in the ordinary course of business. Such matters are subject to many uncertainties, and outcomes are not predictable with assurance. There are no such matters that are included in the condensed financial statements as of March 31, 2015.
	Operating Lease
	In February 2015, the Company entered into a lease agreement for a new and expanded laboratory facility. The laboratory space is leased on a month-to-month basis and is part of a shared facility in Menlo Park, California.
	Rent expense was to $19,015 and $5,400 for the three months ended March 31, 2015 and 2014, respectively. Rent expense for the three months ended March 31, 2015 included $5,700 for the laboratory space in Pasadena, California. The Company terminated its previous lease for the the laboratory space in Pasadena, California effective March 31, 2015.

Stockholders_Equity

Stockholders' Equity	3 Months Ended
	Mar. 31, 2015
Stockholders' Equity Note [Abstract]
Stockholders' Equity Note Disclosure [Text Block]	Note 6 - Stockholders’ Equity
	Authorized Capital
	In January 2015, the Company completed its IPO on the TSX Venture Exchange. The Company sold 11,250,000 units at a price of $1.00 per unit, providing gross proceeds of $11,250,000. Concurrently with the IPO, the Company completed a previously-subscribed private placement of an additional 2,700,000 units for gross proceeds of $2,700,000, resulting in total gross proceeds of $13,950,000. After deducting the offering expenses, the Company received net proceeds of $12,953,484. All units consist of one share of CohBar's common stock and one-half of one common stock purchase warrant.  In the aggregate, a total of 13,950,000 shares of common stock and 6,975,000 warrants to purchase common stock were issued in connection with the IPO and concurrent private placement. Each whole warrant is exercisable to acquire one share of CohBar's common stock at a price of $2.00 per share at any time up to January 6, 2017, subject to CohBar's right to accelerate the expiration time of the warrants if at any time the volume-weighted average trading price of its common stock is equal to or exceeds $3.00 per share for twenty (20) consecutive trading days. The Company also issued compensation options to its agent for the IPO exercisable for an aggregate of 786,696 units at a price of $1.00 per unit at any time prior to July 6, 2016.
	In January 2015, the Company amended its Certificate of Incorporation to increase the total number of authorized shares of common stock. Following the amendment, the Company has authorized the issuance and sale of up to 80,000,000 shares of stock, consisting of 75,000,000 shares of common stock having a par value of $0.001 and 5,000,000 shares of Preferred Stock having a par value of $0.001 per share.   As of March 31, 2015, there were no shares of Preferred Stock outstanding and there were no declared but unpaid dividends or undeclared dividend arrearages on any shares of the Company’s capital stock.
	In January 2015, the Company amended and restated the 2011 Equity Incentive Plan (the “2011 Plan”). The Amendment and Restatement increased the aggregate number of shares of its common stock that may be issued pursuant to stock awards under the plan. In accordance with the rules of the TSX Venture Exchange regarding equity incentive plans, the number of shares that can be reserved for issuance under the 2011 Plan is equal to 20% of the Company’s common stock outstanding at the completion of the offering. The total number of shares reserved for issuance after the completion of the IPO is 6,453,069.
	Preferred Stock
	Upon the completion of the IPO on January 6, 2015 each outstanding share of Series B Preferred Stock was automatically converted into one share of common stock. The Company converted 5,400,000 shares of Series B Preferred Stock into 5,400,000 shares of its common stock.
	Stock Options
	The Company has one incentive stock plan, the 2011 Plan, and has granted stock options to employees, non-employee directors and consultants from the 2011 Plan. Options granted under the Plan may be Incentive Stock Options or Non-statutory Stock Options, as determined by the Administrator at the time of grant. At March 31, 2015, 3,843,258 shares of the Company’s common stock were available for future issuance under the 2011 Plan.
	The Company granted 127,532 stock options during the year ended December 31, 2014 which contained performance conditions that include (i) the optionee’s continuous service and (ii) completion of the Company’s initial public offering pursuant to an effective registration statement under the Securities Act of 1933, as amended. The performance conditions were met during the three months ended March 31, 2015 and the options were valued. The options had an exercise price of $0.26 and a fair value of $0.87. The Company recognized an expense of $39,201 in the three months ended March 31, 2015 for the period from the grant date, October 31, 2013, to the end of the current quarter, March 31, 2015.
	The Company recorded $145,514 and $362 of stock based compensation in the three months ended March 31, 2015 and 2014, respectively.
	The following table represents stock option activity for the three months ended March 31, 2015:
									Weighted Average
			Stock Options						Exercise Price						Fair Value			Contractual		Aggregate
			Outstanding			Exercisable			Outstanding			Exercisable			Vested			Life (Years)		Intrinsic Value
	Balance – December 31, 2014			2,609,811			459,437		$	0.38		$	0.17		$	0.17			9.57	$	-
	Granted			786,696			786,696			1			1			0.38			1.27		-
	Exercised			-55,548			-55,548			-			-			-			-		-
	Cancelled			-			-			-			-			-			-		-
	Balance – March 31, 2015			3,340,959			1,360,374		$	0.62		$	0.31		$	0.31			7.55	$	2,458,311
	The following table summarizes information on stock options outstanding and exercisable as of March 31, 2015:
							Weighted			Weighted						Weighted
	Exercise			Number			Average Remaining			Average			Number			Average
	Price			Outstanding			Contractual Term			Exercise Price			Exercisable			Exercise Price
	$	0.05			72,876			7.01		$	0.05			57,693		$	0.05
	$	0.26			1,061,248			9.03		$	0.26			529,867		$	0.26
	$	0.73			1,475,687			9.63		$	0.73			41,666		$	0.73
	$	1			731,148			1.27		$	1			731,148		$	1
	Totals				3,340,959									1,360,374
	Agent’s Compensation Options
	In connection with the closing of its IPO in January 2015 the Company issued 786,696 compensation options (“Compensation Options”) to the agents that took part in the offering. Each Compensation Option is exercisable for a unit consisting of one share of common stock and one-half of one common stock purchase warrant at an exercise price of $1.00 per unit. The Compensation Options expire on July 6, 2016. Each whole warrant issuable upon exercise of Compensation Options is exercisable to acquire one share of common stock at an exercise price of $2.00 per share at any time up to January 6, 2017, subject to the Company’s right to accelerate the expiration time of the warrants if at any time the volume-weighted average trading price of its common stock is equal to or exceeds $3.00 per share for twenty (20) consecutive trading days. Because the Compensation Options are considered a cost of the IPO, the resulting value is recognized as both an increase and decrease to the equity section of the accompanying condensed balance sheets.
	In March 2015, two agents that took part in the Company’s IPO exercised a total of 55,548 Compensation Options for cash proceeds of $55,548.
	Warrants
	During the three months ended March 31, 2015, the Company issued 7,002,774 common stock purchase warrants consisting of warrants included in the units sold in the IPO and concurrent private placement and issued on exercise of compensation options. The warrants are exercisable through January 6, 2017 at a price of $2.00 per share. The warrants are subject to the Company’s right to accelerate the expiration time of the warrants if at any time the volume-weighted average trading price of its common stock is equal to or exceeds $3.00 per share for twenty (20) consecutive trading days.
	As of March 31, 2015, the Company has 7,936,391 warrants outstanding and exercisable to purchase common stock. Such warrants have a weighted average exercise price of $1.80, a weighted average remaining contractual life of 2.6 years and an aggregate intrinsic value of $1,038,575.

Related_Party_Transactions

Related Party Transactions	3 Months Ended
	Mar. 31, 2015
Related Party Transactions [Abstract]
Related Party Transactions Disclosure [Text Block]	Note 7 – Related Party Transactions
	Two of the Company’s Directors each provide it consulting services pursuant to agreements that provide for annual compensation of $42,000. Each agreement provides for an annual service term and can be extended by mutual consent of both parties. The service terms under the agreements with expire in September 2015 and November 2015, respectively. During the three months ended March 31, 2015 and 2014, payments of $10,500 and $3,000 were made to each Director, respectively.  As of March 31, 2015 and December 31, 2014, no amounts were owed to either Director.

Subsequent_Events

Subsequent Events	3 Months Ended
	Mar. 31, 2015
Subsequent Events [Abstract]
Subsequent Events [Text Block]	Note 8 - Subsequent Events
	Management has evaluated subsequent events to determine if events or transactions occurring through the date on which the financial statements were issued require adjustment or disclosure in the Company’s financial statements.

Summary_of_Significant_Account1

Summary of Significant Accounting Policies (Policies)	3 Months Ended
	Mar. 31, 2015
Accounting Policies [Abstract]
Basis of Accounting, Policy [Policy Text Block]	Basis of Presentation
	All amounts are presented in U.S. Dollars.
Use of Estimates, Policy [Policy Text Block]	Use of Estimates
	The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent liabilities at dates of the financial statements and the reported amounts of revenue and expenses during the periods. Actual results could differ from these estimates. The Company’s significant estimates and assumptions include the fair value of the Company’s stock, stock-based compensation, debt discount and the valuation allowance relating to the Company’s deferred tax assets.
Concentration Risk, Credit Risk, Policy [Policy Text Block]	Concentrations of Credit Risk
	The Company maintains deposits in a financial institution which is insured by the Federal Deposit Insurance Corporation (“FDIC”). At various times, the Company has deposits in this financial institution in excess of the amount insured by the FDIC.
Marketable Securities, Policy [Policy Text Block]	Marketable Securities
	Marketable securities, which consists of U.S Treasury Bills and Certificates of Deposit, are classified as held-to-maturity. Held-to-maturity securities represent those securities that the Company has both a positive intent and ability to hold the security until maturity. The Company determines the appropriate balance sheet classification of its investments at the time of purchase and evaluates the classification at each balance sheet date.
	The Company had $3,247,509 and $0 of held-to-maturity securities at March 31, 2015 and December 31, 2014, respectively.
Deferred Charges, Policy [Policy Text Block]	Deferred Offering Costs
	The Company classifies amounts related to the IPO not closed as of the balance sheet date as Deferred Offering Costs. During the three months ended March 31, 2015, the Company reclassified Deferred Offering Costs in the amount of $749,386 to Additional Paid-in-Capital as an offset to its IPO.
	During the three months ended March 31, 2015, the Company incurred $30,321 of additional offering related costs. These costs were recorded as a reduction in Additional Paid-in-Capital in the accompanying condensed balance sheets.
Fair Value of Financial Instruments, Policy [Policy Text Block]	Fair Value of Financial Instruments
	The Company measures the fair value of financial assets and liabilities based on the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. The Company utilizes three levels of inputs that may be used to measure fair value:
	Level 1 - quoted prices in active markets for identical assets or liabilities
	Level 2 - quoted prices for similar assets and liabilities in active markets or inputs that are observable
	Level 3 - inputs that are unobservable (for example, cash flow modeling inputs based on assumptions)
	The carrying amounts of cash, marketable securities, accounts payable, accrued liabilities and debt approximate fair value due to the short-term nature of these instruments.
Common Stock Purchase Warrants [Policy Text Block]	Common Stock Purchase Warrants
	The Company classifies as equity any contracts that (i) require physical settlement or net-share settlement or (ii) provides the Company with a choice of net-cash settlement or settlement in its own shares (physical settlement or net-share settlement) providing that such contracts are indexed to the Company's own stock. The Company classifies as assets or liabilities any contracts that (i) require net-cash settlement (including a requirement to net cash settle the contract if an event occurs and if that event is outside the Company’s control), or (ii) gives the counterparty a choice of net-cash settlement or settlement in shares (physical settlement or net-share settlement). The Company assesses classification of its common stock purchase warrants and other free standing derivatives at each reporting date to determine whether a change in classification between assets and liabilities is required.  The Company’s free standing derivatives consist of warrants to purchase common stock that were issued in connection with its notes payable, warrants to purchase common stock that were issued in connection with the Company’s IPO and concurrent private placement and compensation options issued to the agent’s in the IPO exercisable for shares of common stock and common stock purchase warrants. The Company evaluated these warrants to assess their proper classification using the applicable criteria enumerated under U.S. GAAP and determined that the common stock purchase warrants meet the criteria for equity classification in the condensed balance sheet as of March 31, 2015 and December 31, 2014.
Share-based Compensation, Option and Incentive Plans Policy [Policy Text Block]	Share-Based Payment
	The Company accounts for share-based payments using the fair value method. For employees and directors, the fair value of the award is measured, as discussed below, on the grant date. For non-employees, fair value is generally valued based on the fair value of the services provided or the fair value of the equity instruments on the measurement date, whichever is more readily determinable and re-measured on each financial reporting dates until the service is complete. The Company has granted stock options at exercise prices no less than the fair market value as determined by the board of directors, with input from management.
	The weighted-average fair value of options and warrants has been estimated on the date of grant using the Black-Scholes pricing model. The fair value of each instrument is estimated on the date of grant utilizing certain assumptions for a risk free interest rate, volatility and expected remaining lives of the awards. Since the Company has a limited history of being publicly traded, the fair value of stock-based payment awards issued before the Company’s IPO  was estimated using a volatility derived from an index of comparable entities. Stock-based awards that were issued during the three months ended March 31, 2015, after the Company’s IPO,  were estimated using the volatility derived from the Company’s common stock, which was not materially different than using an index of Comparable entities. The assumptions used in calculating the fair value of share-based payment awards represent management’s best estimates, but these estimates involve inherent uncertainties and the application of management judgment. As a result, if factors change and the Company uses different assumptions, the Company’s stock-based compensation expense could be materially different in the future. In addition, the Company is required to estimate the expected forfeiture rate and only recognize expense for those shares expected to vest. In estimating the Company’s forfeiture rate, the Company analyzed its historical forfeiture rate, the remaining lives of unvested options, and the number of vested options as a percentage of total options outstanding. If the Company’s actual forfeiture rate is materially different from its estimate, or if the Company reevaluates the forfeiture rate in the future, the stock-based compensation expense could be significantly different from what the Company has recorded in the current period.
	The weighted-average Black-Scholes assumptions are as follows:
		For The Three Months Ended March 31,
		2015			2014
	Expected life		2 years			1 year
	Risk free interest rate		0.65	%		0.13	%
	Expected volatility		80	%		132	%
	Expected dividend yield		0	%		0	%
	As of March 31, 2015, total unrecognized stock option compensation expense is $838,163, which will be recognized as those options vest over a period of approximately four years. The amount of future stock option compensation expense could be affected by any future option grants or by any option holders leaving the Company before their grants are fully vested.
Earnings Per Share, Policy [Policy Text Block]	Net Loss Per Share of Common Stock
	Basic net loss per share is computed by dividing net loss attributable to common stockholders by the weighted average number of common shares outstanding during the period.  Diluted net earnings per share reflects the potential dilution that could occur if securities or other instruments to issue common stock were exercised or converted into common stock.  Potentially dilutive securities are excluded from the computation of diluted net loss per share as their inclusion would be anti-dilutive and consist of the following:
			March 31,			March 31,
			2015			2014
	Warrants			7,936,391			36,542
	Options			3,340,959			163,971
	Convertible notes			-			210,000
	Totals			11,277,350			410,513
New Accounting Pronouncements, Policy [Policy Text Block]	Recent Accounting Pronouncements
	Recent accounting standards that have been issued or proposed by the FASB or other standards-setting bodies that do not require adoption until a future a date are not expected to have a material impact on the Company’s financial statements upon adoption.

Summary_of_Significant_Account2

Summary of Significant Accounting Policies (Tables)	3 Months Ended
	Mar. 31, 2015
Accounting Policies [Abstract]
Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]	The weighted-average Black-Scholes assumptions are as follows:
		For The Three Months Ended March 31,
		2015			2014
	Expected life		2 years			1 year
	Risk free interest rate		0.65	%		0.13	%
	Expected volatility		80	%		132	%
	Expected dividend yield		0	%		0	%
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]	Potentially dilutive securities are excluded from the computation of diluted net loss per share as their inclusion would be anti-dilutive and consist of the following:
			March 31,			March 31,
			2015			2014
	Warrants			7,936,391			36,542
	Options			3,340,959			163,971
	Convertible notes			-			210,000
	Totals			11,277,350			410,513

Accrued_Expenses_Tables

Accrued Expenses (Tables)	3 Months Ended
	Mar. 31, 2015
Payables and Accruals [Abstract]
Schedule of Accrued Liabilities [Table Text Block]	Accrued expenses consist of:
		As of		As of
		March 31, 2015		December 31, 2014
	Lab services	$	36,579	$	64,768
	Professional fees		107,143		173,829
	Consultant fees		52,000		52,000
	Interest		12,559		10,804
	Expense reimbursement		-		4,000
	Total accrued expenses	$	208,281	$	305,401

Stockholders_Equity_Tables

Stockholders' Equity (Tables)	3 Months Ended
	Mar. 31, 2015
Stockholders' Equity Note [Abstract]
Schedule of Share-based Compensation, Stock Options, Activity [Table Text Block]	The following table represents stock option activity for the three months ended March 31, 2015:
									Weighted Average
			Stock Options						Exercise Price						Fair Value			Contractual		Aggregate
			Outstanding			Exercisable			Outstanding			Exercisable			Vested			Life (Years)		Intrinsic Value
	Balance – December 31, 2014			2,609,811			459,437		$	0.38		$	0.17		$	0.17			9.57	$	-
	Granted			786,696			786,696			1			1			0.38			1.27		-
	Exercised			-55,548			-55,548			-			-			-			-		-
	Cancelled			-			-			-			-			-			-		-
	Balance – March 31, 2015			3,340,959			1,360,374		$	0.62		$	0.31		$	0.31			7.55	$	2,458,311
Schedule of Share-based Compensation, Shares Authorized under Stock Option Plans, by Exercise Price Range [Table Text Block]	The following table summarizes information on stock options outstanding and exercisable as of March 31, 2015:
							Weighted			Weighted						Weighted
	Exercise			Number			Average Remaining			Average			Number			Average
	Price			Outstanding			Contractual Term			Exercise Price			Exercisable			Exercise Price
	$	0.05			72,876			7.01		$	0.05			57,693		$	0.05
	$	0.26			1,061,248			9.03		$	0.26			529,867		$	0.26
	$	0.73			1,475,687			9.63		$	0.73			41,666		$	0.73
	$	1			731,148			1.27		$	1			731,148		$	1
	Totals				3,340,959									1,360,374

Managements_Liquidity_Plans_De

Management's Liquidity Plans (Details Textual) (USD $)	1 Months Ended	3 Months Ended
	Jan. 31, 2015	Mar. 31, 2015	Mar. 31, 2014	Dec. 31, 2014
Subsidiary, Sale of Stock [Line Items]
Working Capital		$12,835,370
Stockholders' Equity Attributable to Parent		12,663,179		1,069,604
Net Loss		781,265	254,410
Proceeds from Issuance of Common Stock	13,950,000
IPO [Member]
Subsidiary, Sale of Stock [Line Items]
Stock Issued During Period, Shares, New Issues	11,250,000
Share Price	$1	$1
Stock Issued During Period, Value, New Issues	11,250,000
Private Placement [Member]
Subsidiary, Sale of Stock [Line Items]
Stock Issued During Period, Shares, New Issues	2,700,000
Stock Issued During Period, Value, New Issues	$2,700,000

Summary_of_Significant_Account3

Summary of Significant Accounting Policies (Details)	3 Months Ended
	Mar. 31, 2015	Mar. 31, 2014
Weighted Average [Line Items]
Expected life	2 years	1 year
Risk free interest rate	0.65%	0.13%
Expected volatility	80.00%	132.00%
Expected dividend yield	0.00%	0.00%

Summary_of_Significant_Account4

Summary of Significant Accounting Policies (Details 1)	3 Months Ended
	Mar. 31, 2015	Mar. 31, 2014
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	11,277,350	410,513
Warrant [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	7,936,391	36,542
Equity Option [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	3,340,959	163,971
Convertible Debt Securities [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	0	210,000

Summary_of_Significant_Account5

Summary of Significant Accounting Policies (Details Textaul) (USD $)	3 Months Ended
	Mar. 31, 2015	Mar. 31, 2014	Dec. 31, 2014
Marketable Securities, Current	$3,247,509		$0
Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs	749,386
Employee Service Share-based Compensation, Nonvested Awards, Compensation Not yet Recognized, Stock Options	838,163
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Remaining Contractual Term	4 years
Payments Of Deferred Offering Costs	$30,321	$14,982

Accrued_Expenses_Details

Accrued Expenses (Details) (USD $)	Mar. 31, 2015	Dec. 31, 2014
Accrued Expenses [Line Items]
Lab services	$36,579	$64,768
Professional fees	107,143	173,829
Consultant fees	52,000	52,000
Interest	12,559	10,804
Expense reimbursement	0	4,000
Total accrued expenses	$208,281	$305,401

Commitments_and_Contingencies_

Commitments and Contingencies (Details Textual) (USD $)	3 Months Ended
	Mar. 31, 2015	Mar. 31, 2014
Operating Leased Assets [Line Items]
Operating Leases, Rent Expense, Net	$19,015	$5,400
Laboratory Space [Member]
Operating Leased Assets [Line Items]
Operating Leases, Rent Expense, Net	$5,700

Stockholders_Equity_Details

Stockholders' Equity (Details) (USD $)	3 Months Ended	12 Months Ended
	Mar. 31, 2015	Dec. 31, 2014
Stock Options Outstanding
Balance - December 31, 2014	2,609,811
Granted	786,696
Exercised	-55,548
Cancelled	0
Balance - March 31, 2015	3,340,959	2,609,811
Stock Options Exercisable
Balance - December 31, 2014	459,437
Granted	786,696
Exercised	-55,548
Cancelled	0
Balance - March 31, 2015	1,360,374	459,437
Weighted Average Exercise Price Outstanding
Balance - December 31, 2014	$0.38
Granted	$1
Exercised	$0
Cancelled	$0
Balance - March 31, 2015	$0.62	$0.38
Weighted Average Exercise Price Exercisable
Balance - December 31, 2014	$0.17
Granted	$1
Exercised	$0
Cancelled	$0
Balance - March 31, 2015	$0.31	$0.17
Weighted Average Fair Value Vested
Balance - December 31, 2014	$0.17
Granted	$0.38
Exercised	$0
Cancelled	$0
Balance - March 31, 2015	$0.31	$0.17
Weighted Average Contractual Life (Years)
Granted	1 year 3 months 7 days
Exercised	0 years
Cancelled	0 years
Balance	7 years 6 months 18 days	9 years 6 months 25 days
Aggregate Intrinsic Value
Balance - December 31, 2014	$0
Granted	0
Exercised	0
Cancelled	0
Balance - March 31, 2015	$2,458,311	$0

Stockholders_Equity_Details_1

Stockholders' Equity (Details 1) (USD $)	3 Months Ended
	Mar. 31, 2015
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Stock Options Number Outstanding	3,340,959
Stock Options Number Exercisable	1,360,374
Exercise Price 0.05 [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Stock Options Number Outstanding	72,876
Stock Options Outstanding Weighted Average Remaining Contractual Term	7 years 4 days
Stock Options Outstanding Weighted Average Exercise Price	$0.05
Stock Options Number Exercisable	57,693
Stock Options Exercisable Weighted Average Exercise Price	$0.05
Exercise Price 0.26 [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Stock Options Number Outstanding	1,061,248
Stock Options Outstanding Weighted Average Remaining Contractual Term	9 years 11 days
Stock Options Outstanding Weighted Average Exercise Price	$0.26
Stock Options Number Exercisable	529,867
Stock Options Exercisable Weighted Average Exercise Price	$0.26
Exercise Price 0.73 [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Stock Options Number Outstanding	1,475,687
Stock Options Outstanding Weighted Average Remaining Contractual Term	9 years 7 months 17 days
Stock Options Outstanding Weighted Average Exercise Price	$0.73
Stock Options Number Exercisable	41,666
Stock Options Exercisable Weighted Average Exercise Price	$0.73
Exercise Price 1 [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Stock Options Number Outstanding	731,148
Stock Options Outstanding Weighted Average Remaining Contractual Term	1 year 3 months 7 days
Stock Options Outstanding Weighted Average Exercise Price	$1
Stock Options Number Exercisable	731,148
Stock Options Exercisable Weighted Average Exercise Price	$1

Stockholders_Equity_Details_Te

Stockholders' Equity (Details Textual) (USD $)	3 Months Ended		1 Months Ended	12 Months Ended	1 Months Ended	0 Months Ended
	Mar. 31, 2015	Mar. 31, 2014	Mar. 31, 2015	Dec. 31, 2014	Jan. 31, 2015	Jan. 06, 2015
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross	786,696
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price	$1
Common Stock, Shares Authorized	75,000,000		75,000,000	75,000,000
Common Stock, Par or Stated Value Per Share	$0.00		$0.00	$0.00
Preferred Stock, Shares Authorized	5,000,000		5,000,000	5,000,000
Preferred Stock, Par or Stated Value Per Share	$0.00		$0.00	$0.00
Equity Incentive Plan Description	In accordance with the rules of the TSX Venture Exchange regarding equity incentive plans, the number of shares that can be reserved for issuance under the 2011 Plan is equal to 20% of the Companys common stock outstanding at the completion of the offering.
Common Stock, Capital Shares Reserved for Future Issuance	3,843,258		3,843,258
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value	$0.38
Share-based Compensation	$145,514	$362
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period	55,548
Proceeds from Stock Options Exercised	55,548	0
Two Agent [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period			55,548
Proceeds from Stock Options Exercised			55,548
Employee Stock Option [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross				127,532
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price				$0.26
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value				$0.87
Payments of Stock Issuance Costs	39,201
Compensation Options [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross					786,696
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price					$1
Class of Warrant or Right, Title of Security Warrants or Rights Outstanding					The Compensation Options expire on July 6, 2016. Each whole warrant issuable upon exercise of Compensation Options is exercisable to acquire one share of common stock at an exercise price of $2.00 per share at any time up to January 6, 2017, subject to the Companys right to accelerate the expiration time of the warrants if at any time the volume-weighted average trading price of its common stock is equal to or exceeds $3.00 per share for twenty (20) consecutive trading days.
Common Stock [Member]
Conversion of Stock, Shares Issued						5,400,000
Warrant [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number	7,936,391		7,936,391
Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Exercise Price	$1.80		$1.80
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Outstanding, Weighted Average Remaining Contractual Terms	2 years 7 months 6 days
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Outstanding	1,038,575		1,038,575
Amendment [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized					80,000,000
Common Stock, Shares Authorized					75,000,000
Common Stock, Par or Stated Value Per Share					$0.00
Preferred Stock, Shares Authorized					5,000,000
Preferred Stock, Par or Stated Value Per Share					$0.00
IPO and Private Placement [Member]
Warrants To Purchase Common Stock					6,975,000
Proceeds from Issuance or Sale of Equity					13,950,000
Stock Issued During Period, Shares, New Issues					13,950,000
Class of Warrant or Right, Title of Security Warrants or Rights Outstanding					Each whole warrant is exercisable to acquire one share of CohBar's common stock at a price of $2.00 per share at any time up to January 6, 2017, subject to CohBar's right to accelerate the expiration time of the warrants if at any time the volume-weighted average trading price of its common stock is equal to or exceeds $3.00 per share for twenty (20) consecutive trading days.
Proceeds from Debt, Net of Issuance Costs					12,953,484
IPO [Member]
Class Of Warrant Or Rights Issued During Period					11,250,000
Share Price	$1		$1		$1
Proceeds from Issuance of Warrants					11,250,000
Stock Issued During Period, Shares, New Issues					11,250,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross					786,696
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price					$1
Common Stock, Capital Shares Reserved for Future Issuance					6,453,069
Private Placement [Member]
Class Of Warrant Or Rights Issued During Period					2,700,000
Proceeds from Issuance of Warrants					$2,700,000
Stock Issued During Period, Shares, New Issues					2,700,000
Series B Preferred Stock [Member]
Conversion of Stock, Shares Converted						5,400,000

Related_Party_Transactions_Det

Related Party Transactions (Details Textual) (Two Directors [Member], USD $)	3 Months Ended
	Mar. 31, 2015	Mar. 31, 2014
Two Directors [Member]
Deferred Compensation Arrangement with Individual, Excluding Share-based Payments and Postretirement Benefits [Line Items]
Deferred Compensation Arrangement with Individual, Compensation Expense	$42,000
Deferred Compensation Arrangement with Individual, Distributions Paid	$10,500	$3,000